

S/N 09/117,071



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	KINGSMAN ET AL.	Examiner:	G. LEE
Serial No.:	09/117,071	Group Art Unit:	1632
Filed:	SEPTEMBER 25, 1998	Docket No.:	9192.5USWO
Title:	RETROVIRAL VECTOR AND ITS USE IN GENE THERAPY		

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on October 26, 2000.

By: [Signature]

Name: \_\_\_\_\_

**SUPPLEMENTAL AMENDMENT & RESPONSE**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In addition to the Amendment and Response mailed September 27, 2000, Applicants submit the following amendments and remarks in response to the Office Action mailed March 28, 2000.

**IN THE CLAIMS**

Please cancel claims 57 and 62, added by the Amendment of September 27, 2000 (without prejudice); amend claims 47, 51, 59 and 61; and add claim 63 as follows:

47. (AMENDED) A method for introducing a heterologous gene into a target cell in a subject, which comprises the following steps:

(i) conversion of a subject's cell into a producer cell [capable of producing a replication defective retroviral vector], comprising introducing into the subject's cell:

first DNA sequence encoding a replication defective retroviral vector, which comprises

defective retroviral genome lacking functional *env* and functional *gag* *pol* genes [but having the remaining components essential for retroviral functions]; and